Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016517 · ClinicalTrials.gov registry record
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
A clinical trial, sponsored by Tufts Medical Center.
- Not yet
- Registry status
- 18
- Enrollment target
NCT06016517: Clinical Trial study, sponsored by Tufts Medical Center.
NCT06016517 is a clinical trial that has not yet begun recruiting, run by Tufts Medical Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016517 has not yet begun recruiting, sponsored by Tufts Medical Center.
- NOT YET RECRUITING
- Registry status
- 18 participants
- Enrollment target
Study Summary
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are: * What are the effects of different treatments on RA symptoms and condition for each individual patient * What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).
Primary Outcome
Evaluates patient and physician overall assessment of disease activity, including the number of swollen and painful joints (out of 28 joints),
Interventions
- DRUG Adalimumab
- DRUG Upadacitinib
- DRUG Tocilizumab
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-12-01 |
What is known before NCT06016517 opens enrollment
NCT06016517 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT06016517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06016517 about?
NCT06016517 is a clinical study titled "Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis". The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, fin...
What is the current status of trial NCT06016517?
This trial is currently not yet recruiting. The enrollment target is 18 participants. The study started on 2026-05-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT06016517?
The interventions under investigation include: Adalimumab (DRUG), Upadacitinib (DRUG), Tocilizumab (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT06016517?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI